Oatly stock slides 5% premarket as earnings fall short of estimates hurt by COVID restrictions in Asia, strong dollar


Oatly Group AB OTLY, +16.11% stock slid 5% in premarket trade Monday, after the Swedish maker of oat-based dairy products posted a wider-than-expected third-quarter loss and revenue that fell short of estimates. The company had a net loss of $107.9 million, or 18 cents a share, in the quarter, wider than the loss of $41.2 million, or 7 cents a share, posted in the year-earlier period. Revenue rose to $183.0 million from $171.1 million a year ago. The FactSet consensus was for a loss of 10 cents and revenue of $210 million. “Third quarter financial results were below our expectations, largely driven by COVID-19 restrictions in Asia, production challenges in the Americas, and continued foreign exchange headwinds,’ Chief Executive Toni Petersson said in a statement. The company has taken strategic measures to adapt its supply chain network and simply its structure with the aim of using an asset-light approach to improving profitability. “The framework for the supply chain network strategy is centered on focusing investments on Oatly’s proprietary oat-base technology and capacity, which is expected to reduce the capital intensity of future facilities and have a positive effect on our cash flow outlook,” said the statement. Oatly is also pursuing manufacturing partners to create a hybrid production network in certain regions. It expects to cut overhead and head count to cut up to 25% of costs related to group corporate functions and regional EMEA layers, seeking up to $25 million in annual svings in the first half of 2023. Oatly is now expecting full-year revenue of $700 million to $720 million, compared with consensus of $793.20 million. The stock has fallen 69% in the year to date, while the S&P 500 SPX, +0.92% has fallen 16%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleThe New York Post: Gunman on the loose at University of Virginia following shooting
Next articleBiogen shares rally on failure of trials for rival Alzheimer drug


Please enter your comment!
Please enter your name here